UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 9, 2004
----------
SIGA Technologies, Inc.
-----------------------
(Exact Name of Registrant as Specified in Charter)
Delaware
--------
(State or other Jurisdiction of
Incorporation or Organization)
0-23047 13-3864870
------- ----------
(Commission File (I.R.S. Employer
Number) Identification Number)
420 Lexington Avenue, Suite 601
New York, New York 10170
------------------------------- -----
(Address of Principal Executive Offices) (Zip Code)
(212) 672-9100
--------------
(Registrant's telephone number, including area code)
ITEM 5. Other Events and Required FD Disclosure.
On June 9, 2004, SIGA Technologies, Inc., a Delaware corporation ("SIGA"),
issued a press release pursuant to which SIGA announced the signing of an Asset
Purchase Agreement to acquire certain antiviral programs targeting potential
agents of biological warfare from ViroPharma Incorporated (VPHM) for a purchase
price of $1 million in cash and 1 million shares of SIGA common stock. SIGA will
purchase lead compounds, assays and scientific know-how related to development
of antiviral drugs, including those targeting smallpox and hemorrhagic fever
viruses such as the Ebola virus. The research programs being acquired are
currently the subject of grants from the National Institutes of Health (NIH).
The closing of the acquisition is subject to customary closing conditions,
including obtaining approval of the transfer of the grants.
For a description of the events reported pursuant to this Form 8-K,
reference is made to the press release issued by SIGA on June 9, 2004, the text
of which is attached hereto as Exhibit 99.1.
ITEM 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
Exhibit No. Description
----------- -----------
99.1 Press Release dated June 9, 2004.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SIGA TECHNOLOGIES, INC.
By: /s/ Thomas N. Konatich
--------------------------------------
Thomas N. Konatich
Acting Chief Executive Officer and
Chief Financial Officer
Date: June 9, 2004
3
EXHIBIT INDEX
Exhibit Number Description
-------------- -----------
99.1 Press Release dated June 9, 2004.
4